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Dear editor, 
We read with great interest the study of Montano-Loza et al
1
 regarding outcomes after liver 
transplantation for primary biliary cholangitis (PBC) and factors associated with its recurrence. We 
first want to congratulate the authors for their work reporting the largest multicentric cohort 
published, allowing the identification of risk factors of PBC recurrence like young age at liver 
transplant, presence of biochemical markers of cholestasis after transplant, and use of tacrolimus. 
However, regarding the impact of the immunosuppressive drugs, we believe that the authors’ 
conclusions might benefit from further analysis. 
Indeed, tacrolimus seems to be associated with a higher risk of PBC recurrence compared to 
cyclosporine in univariate analysis (Kaplan-Meier curves with log-rank test) with a higher 5-year 
recurrence rate of 28% vs 11% (p<0.001). This finding was confirmed by the univariate Cox analysis 
with a hazard ratio (HR) for tacrolimus of 2.31 (p<0.001) and 0.62 (p=0.001) for cyclosporine, 
suggesting a protective effect of cyclosporine compared to tacrolimus. However, in multivariate 
analysis, all immunosuppressive drugs have a HR higher than 1 suggesting that other factors 
associated with the use of cyclosporine mitigate its putative protective effect. A significant p-value 
was observed only for tacrolimus and mycophenolate mofetil. Regarding cyclosporine the p-value did 
not reach significance (p=0.052 in model 1 and p=0.07 in model 2) maybe because of a lack of power 
(i.e. 28% of patients had cyclosporine). 
As all drugs have an HR superior to 1 (taking as reference the absence of this drug) in multivariate 
analysis, they could be considered as risks factors for recurrence and therefore one could conclude 
that the absence of immunosuppressive drugs may prevent PBC recurrence. However, an 
immunosuppressive drug regimen is mandatory after liver transplant and usually includes a main 
drug (mostly a calcineurin inhibitor) and often a second drug.  
We believe that this misinterpretation could be prevented by further statistical analysis of the 
available data. 
Indeed, the main immunosuppressive drugs should be compared to each other and entered in the 
multivariate model as a unique categorical variable with different modalities (i.e. tacrolimus or 
cyclosporine or other drugs) allowing calculation of an HR and a p-value for each drug in comparison 
to one drug (which will be considered as reference treatment with a HR=1). A second categorical 
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variable could be set up to take the second line immunosuppressive drug into account. This would 
provide a clearer idea of the potential benefit of each immunosuppressive regimen. If the main 
immunosuppressive therapy changed during the first year, this categorical variable should be 
analyzed as a time dependent covariate in the multivariate cox model. 
We hope that clarifying this point may allow the authors to provide clear recommendations 
regarding the best immunosuppressive regimen for these patients. 
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